38 results about "FOXO1" patented technology

The invention relates to a benzimidazole derivative 2-m-phenylaminobenzimidazolyl-1H-pyrazolyl-3-formamide of which the structural formula is disclosed in the specification. The benzimidazole derivative can promote growth of microzyme, enhance the metabolic activity of the microzyme, obviously lower the plasma triglyceride, total cholesterol and high density lipoprotein of a C57 BL/6J mouse which is fed by high-fat feed for a long time, lower the contractive pressure and diastolic pressure of the model mouse, lower the fasting blood-glucose of the model mouse, improve the sugar tolerance of the mouse, influence the expression of SIRT1 and related genes (FOXO1, P53, PPARgamma and PGC-1alpha), and obviously improve the metabolism of glucose and fat; and therefore, the benzimidazole derivative can be used for preparing medicines for preventing and treating diabetes and complications thereof.

The invention relates to the technical field of gene polymorphism detection, in particular to a detection method of yak FOXO1 gene single nucleotide polymorphism and a kit thereof. The detection method comprises the following steps: 1) preparing a yak FOXO1 gene amplification product; 2) synthesizing a high and low temperature interior label; 3) preparing an HRM-PCR (High Resolution Melt-Polymerase Chain Reaction) amplification product; 4) collecting a fluorescence signal. Compared with an HRM method used for detecting polymorphic sites in the prior art, a gene probe designed by the detection method is more accurate and flexible in positioning, is accurate in parting, does not need PCR post-processing, has high working efficiency and good repeatability and is low in sample quality and quantity requirements, especially, the concentration requirement of a DNA template can be lowered to 0.1ng/mu L, and time and labor are saved when a sample size is large. Meanwhile, the detection kit has the advantages of high sensitiveness, high detection speed and good stability.

A method for detecting a modulator of transcription of a human PPAR gene promoter is provided, comprising contacting a candidate compound with a cell transfected with an expression vector containing a heterologous gene operably linked to a PPAR promoter and an additional expression vector containing the FOXO1 gene, and comparing the level of expression of said heterologous gene in the presence of the compound and in the absence thereof, whereby a modulator of transcription of the human PPAR gene promoter is identified. The PPAR gene promoter is preferably the PPARγ2 promoter, and the DNA-binding domain of the FOXO1 protein binds to a sequence encompassing the 63 to 323 bp region of the human PPARγ2 promoter, preferably the 270 to 310 bp region.

The invention belongs to the field of biological medicine and particularly relates to an application of a FoxO1 gene in drug preparation. According to the invention, the function of the FoxO1 gene in osteoblast proliferation differentiation under high sugar condition is researched so as to research the function of the FoxO1 gene in bone injury and osteoporosis induced by diabetes, in order to provide theoretical basis and experimental data for clinical treatment of diabetic bone injury and osteoporosis disease. The invention verifies that the FoxO1 gene can promote osteoblast proliferation, FoxO1 is used as a factor used for mainly regulating and controlling bone mass and has an antioxidant stress function on osteoblast, the FoxO1 gene generates a certain protection function on osteoporosis no matter in environment with increased oxidative stress level caused by ageing or diabetes or high blood sugar, and provides a new target for research and development of new anti-osteoporosis drugs.

The present invention relates to methods and kits for diagnosing ulcerative colitis in a subject. In particular, the present invention relates to a method for diagnosing ulcerative colitis in a subject comprising the steps consisting of determining in a sample obtained from the subject the expression level of at least one gene selected from the group consisting of ADH4, ADH6, ADHFE1, AKR1A1, AKR7A2, ALDH1A3, ALDH1L1, ALDH7A1, AOX1, BCHE, CBR3, CES1, CYP1B1, CYP2E1, CYP2W1, CYP4F11, CYP51A1, ESD, KCNAB2, COMT, GSTA4, GSTP1, INMT, MGST2, SULT2A1, TPMT, UGT1A4, UGT1A9, UGT2B7, ABCA1, ABCA2, ABCB1, ABCC1, ABCC10, ABCC5, ABCC6, ABCG2, ATP7A, SLC1A3, SLC7A5, SLC10A2, SLC15A1, SLC15A2, SLC19A2, SLC19A3, SLC22A3, SLC28A3, SLC29A2, SLC38A1, SLC38A5, SLC47A1, SLCO2B1, SLCO4C1, ARNT, FOXO1, HIF3A, NCOA2, NCOR2, NR1H3, NR3C1, PPARD, PPARGC1A, RARB, RXRB, and THRB.

The present invention relates to a method of preparing vascular endothelial cells by transforming (transdifferentiating) adult fibroblasts and a composition, which includes vascular endothelial cells prepared according to the method, for preventing and treating ischemic diseases, the method including a step of transducing adult fibroblasts with a gene. In particular, the present invention confirms that five factors, Foxo1, Er71, Klf2, Tal1, and Lmo2, induce transdifferentiation of adult fibroblasts into induced vascular endothelial cells. Furthermore, the present invention confirms that three factors, Er71, Klf2, and Tal1 induce transdifferentiation of human adult fibroblasts into induced vascular endothelial cells. The resultant induced endothelial cells enable lower limb salvaging by angiogenesis in lower limb ischemic animal models, showing that the induced endothelial cells can be effectively used for prevention or treatment of ischemic diseases.

The invention relates to a grass carp FoxO1 polypeptide antigen and an antibody and a preparation method and application thereof, and belongs to the technical field of biochemistry and molecular immunology. According to the invention, the secondary structure, immunogenicity, hydrophilicity, hydrophobicity, surface probability and the like of a full-length functional protein amino acid sequence ofthe grass carp FoxO1 are analyzed, it is found that 15 amino acids of the grass carp FoxO1 polypeptide antigen, close to the N end, are strong in antigenicity, hydrophilicity and surface probability,therefore the 15 amino acids are used as the suitable grass carp FoxO1 polypeptide antigen. The polyclonal antibody for resisting the grass carp FoxO1 polypeptide antigen is prepared by immunizing NewZealand rabbits by taking the FoxO1 polypeptide antigen as an immunogen. The polyclonal antibody has the advantages of specifically recognizing the FoxO1 full-length functional protein in grass carptissues, filling in the blanks in the field of detection and research of the FoxO1 full-length functional protein of the grass carp, and laying a foundation for the research of regulating the fat metabolism function of an animal by the full-length functional protein of the grass carp FoxO1.

The invention discloses a use of epigallocatechin gallate (EGCG) in preparation of a food and a drug for preventing and treating myocardial energy metabolism disorders. An EGCG action target is an intracellular FoxO1 signal channel. EGCG can inhibit myocardial energy metabolism disorders-caused myocardial cell autophagy and relieve myocardial mitochondria loss. EGCG has an effective concentration of 20 micromoles per liter to myocardial cells, or based on individual weight, an intake ratio of EGCG is 5-10mg/kg/day. EGCG can adjust a myocardial energy metabolism capacity, recover energy metabolism disorders-caused myocardial cell incompetence, inhibit myocardial cell H9c2 glycometabolism disorders-related autophagy increasing, inhibit myocardial cell H9c2 glycometabolism disorders-related oxidative stress, and reduce myocardial cell H9c2 glycometabolism disorders-related insulin resistance. EGCG as a food functional factor and a drug can be used for preventing and treating diseases such as myocardial damage caused by myocardial energy metabolism disorders, myocardial insulin resistance and hyperglycemia.

The invention provides a method for directly transdifferentiating mesenchymal stem cells into sperms by using a transcription factor FOXO1, comprising the following specific steps: introducing the transcription factor FOXO1 into the mesenchymal stem cells in a transfection mode, and carrying out induced culture on the mesenchymal stem cells to obtain the sperms. According to the method, the transcription factor FOXO1 is introduced into mesenchymal stem cells, and the mesenchymal stem cells are induced to develop towards sperms, so that not only can a regulatory mechanism of the stem cells on the vital movement of the organism be known, but also a signal path for maintaining the dynamic balance of the spermatogonial stem cells SSCs is discussed, and a new scheme for inheriting biological information of a male infertility patient, especially a male azoospermia patient, is provided.

The present invention relates to uses of glycerokinase as a glucose metabolism disorder treatment target. According to the present invention, the results show that glycerokinase can catalyze glycerol to generate 3-phosphoglycerol so as to participate in gluconeogenesis, can regulate the expressions of gluconeogenesis enzyme glucose-6-phosphatase (G6pase) and phosphoenolpyruvate carboxykinase (PEPCK) through an AKT-FOXO1 signaling pathway so as to regulate gluconeogenesis, and can provide important effects in the maintaining of the blood glucose homeostasis, such that the glycerokinase and the regulator thereof are the new target for blood glucose regulation and diabetes treatment.

In one aspect, methods of diagnosing a subject as having Alzheimer's disease and prognosing a subject as being at risk of progressing to Alzheimer's disease are provided. In some embodiments, the method comprises determining one or more of the level of expression of rhotekin 2 (RTKN2), the level of expression of microtubule-associated Ser/Thr kinase 4 (MAST4), the level of binding of forkhead box O1 (FOXO1) to the RTKN2 promoter, and the level of binding of amyloid precursor protein (APP) to the MAST4 promoter in a sample from the subject.

The invention relates to the field of preservation of medical materials, in particular to a preparation method and application of a cell, tissue or organ cold preservation solution. According to a cold adaptation mechanism and a patent WO2019/040359 A1 discovered by early hibernation mode animal research of the inventor, extension is performed, and the in-vitro cold preservation effect of donor cells, tissues or organs is improved by regulating and controlling nucleus entry of FOXO1 through a medicine. Taking cornea cold preservation as an example, under the cold preservation strategy that C6 ceramide, Apigenin and Pi are added into the novel cornea preservation solution, corneal endothelial cells survive better, the death rate is only 2.5%, and the corneal permeability is improved. The quality of cornea in-vitro cold preservation is guaranteed, and more selectable cornea donors are provided for successfully carrying out a transplantation operation. The hibernation cold adaptation is based on effectiveness in different tissues and different species, and it is prompted that we can perform improved development of preserving fluid for different species and different organs.

Various embodiments relate to a compound (represented by Formula I) or a pharmaceutically acceptable salt or tautomer thereof. The compound may selectively inhibit a Forkhead Box O1 (FOXO1) transcription factor. Various embodiments relate to methods comprising administering to a mammal having a disease or disorder associated with impaired pancreatic endocrine function, a therapeutically effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof. Various embodiments relate to methods for producing enteroendocrine cells that make and secrete insulin in a mammal, comprising administering to the mammal an effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof.

The invention relates to the technical field of biomedical examination, in particular to a kit for detecting fusion gene related circular RNA-F-circP3F in paraffin-embedded tissue of rhabdomyosarcoma, which comprises a reagent for detecting a molecular marker F-circP3F of rhabdomyosarcoma and a fusion gene PAX3-FOXO1, a primer composition and a probe. The nucleotide sequence of the molecular marker F-circP3F is as shown in SEQ ID No. 1 (sequence identifier number 1). The invention provides the kit and the method for detecting F-circP3F in the paraffin-embedded tissue of rhabdomyosarcoma on the basis of one-step RT-PCR and qRT-PCR technologies, absolute quantitative detection of F-circP3F mRNA in the paraffin-embedded tissue can be realized, the operability and the repeatability are high, the kit and the method can be used for batch detection, the sensitivity and the specificity are relatively high, and the kit and the method can be used for detecting F-circP3F in the paraffin-embedded tissue of rhabdomyosarcoma. And diagnosis, typing and prognosis evaluation of rhabdomyosarcoma are facilitated.

The invention provides a composition for inhibiting calcification of endothelial progenitor cells and a detection kit. The composition for inhibiting the calcification of endothelial progenitor cellscomprises one of over-expression plasmids of Sox9, interference plasmids of ZBTB16, interference plasmids of FOXO1 and interference plasmids of Galectin-2 or a combination of at least two of the components above. The composition for inhibiting the calcification of endothelial progenitor cells can effectively reduce the formation of EPC mineralized nodules induced by an osteogenesis induction culture medium and simultaneously reduce the expression of a bone morphogenetic protein BMP-2. Furthermore, the provided detection kit can remind a user of the risk of vascular calcification, help to screen patients who need further detection, and improve the diagnosis and treatment efficiency.